Muna  Bhanji net worth and biography

Muna Bhanji Biography and Net Worth

Director of Cytokinetics

Muna Bhanji has served as a member of our Board of Directors since February 2021.

Her prior experience includes a 30+ year tenure at Merck, during which she held a number of senior leadership roles within the US and Global commercial organizations driving growth across a broad portfolio of medicines and vaccines of over $40+ billion annually. Most recently, through December 2020, she served as the Senior Vice President, Global Market Access & Policy with responsibility for enabling payer reimbursement and access for patients, for Merck’s products around the world. Muna Bhanji is the Founder and President, TIBA Global Access, a commercialization and market access strategy consultancy serving the biopharmaceutical industry. She currently serves on the board of directors of Corus International, an ensemble of faith-based organizations working at the intersection of poverty alleviation and healthcare, in the most underserved parts of the world. She has also served on the board of directors of Possible Health, a Nepal based NGO, providing integrated, high quality, affordable healthcare to rural communities. Prior board of director service includes serving on the board of directors of the Foundation of Managed Care Pharmacy and chairing Merck’s Supervisory Board in the Netherlands. Muna earned her Bachelor of Pharmacy degree from Rutgers School of Pharmacy and an MBA from St. Joseph’s University.

What is Muna Bhanji's net worth?

The estimated net worth of Muna Bhanji is at least $1.24 million as of June 10th, 2024. Ms. Bhanji owns 23,105 shares of Cytokinetics stock worth more than $1,236,580 as of June 24th. This net worth evaluation does not reflect any other investments that Ms. Bhanji may own. Learn More about Muna Bhanji's net worth.

How do I contact Muna Bhanji?

The corporate mailing address for Ms. Bhanji and other Cytokinetics executives is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Cytokinetics can also be reached via phone at (650) 624-3000 and via email at [email protected]. Learn More on Muna Bhanji's contact information.

Has Muna Bhanji been buying or selling shares of Cytokinetics?

During the last quarter, Muna Bhanji has sold $104,140.00 in shares of Cytokinetics stock. Most recently, Muna Bhanji sold 2,000 shares of the business's stock in a transaction on Monday, June 10th. The shares were sold at an average price of $52.07, for a transaction totalling $104,140.00. Following the completion of the sale, the director now directly owns 17,631 shares of the company's stock, valued at $918,046.17. Learn More on Muna Bhanji's trading history.

Who are Cytokinetics' active insiders?

Cytokinetics' insider roster includes Muna Bhanji (Director), Robert Blum (CEO), Santo Costa (Director), David Cragg (Insider), L. Gage (Director), John Henderson (Director), Ching Jaw (CFO), Edward Kaye (Director), Fady Malik (EVP), B. Parshall (Director), Mark Schlossberg (SVP), Sandford Smith (Director), Wendall Wierenga (Director), and Robert Wong (CAO). Learn More on Cytokinetics' active insiders.

Are insiders buying or selling shares of Cytokinetics?

During the last year, insiders at the biopharmaceutical company sold shares 35 times. They sold a total of 414,500 shares worth more than $23,431,609.18. The most recent insider tranaction occured on June, 17th when Director B Lynne Parshall sold 5,000 shares worth more than $262,750.00. Insiders at Cytokinetics own 3.4% of the company. Learn More about insider trades at Cytokinetics.

Information on this page was last updated on 6/17/2024.

Muna Bhanji Insider Trading History at Cytokinetics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/10/2024Sell2,000$52.07$104,140.0017,631View SEC Filing Icon  
7/7/2023Sell2,000$34.12$68,240.0014,031View SEC Filing Icon  
See Full Table

Muna Bhanji Buying and Selling Activity at Cytokinetics

This chart shows Muna Bhanji's buying and selling at Cytokinetics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cytokinetics Company Overview

Cytokinetics logo
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $53.90
Low: $53.01
High: $54.57

50 Day Range

MA: $58.23
Low: $47.86
High: $69.00

2 Week Range

Now: $53.90
Low: $25.98
High: $110.25


1,080,323 shs

Average Volume

2,727,383 shs

Market Capitalization

$5.65 billion

P/E Ratio


Dividend Yield